Expert Opinion On Drug Safety

Scope & Guideline

Elevating Standards in Pharmacological Research

Introduction

Welcome to the Expert Opinion On Drug Safety information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Expert Opinion On Drug Safety, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1474-0338
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2002 to 2024
AbbreviationEXPERT OPIN DRUG SAF / Expert Opin. Drug Saf.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

Expert Opinion On Drug Safety focuses on the evaluation and analysis of drug safety profiles, particularly through pharmacovigilance studies. It aims to inform healthcare professionals and researchers about the risks and benefits associated with pharmaceutical therapies, utilizing real-world data and systematic reviews to derive insights into drug safety.
  1. Pharmacovigilance and Drug Safety Analysis:
    The journal emphasizes the importance of pharmacovigilance, aiming to monitor, assess, and understand adverse drug reactions and safety signals associated with various medications.
  2. Clinical Safety Evaluations:
    It provides comprehensive evaluations of drug safety through systematic reviews, meta-analyses, and real-world studies, offering insights into the efficacy and safety of drugs across multiple therapeutic areas.
  3. Risk-Benefit Assessments:
    The journal focuses on the balance between the therapeutic benefits of drugs and their potential risks, providing guidance for clinicians in making informed treatment decisions.
  4. Emerging Drug Safety Concerns:
    It addresses new and emerging safety concerns related to drugs, particularly in the context of novel therapies and changing treatment paradigms.
  5. Real-World Evidence Integration:
    The journal integrates real-world evidence to enhance understanding of drug safety in diverse populations and clinical settings, ensuring that findings are applicable to everyday medical practice.
The journal has witnessed the emergence of several key themes that reflect current trends in drug safety research. These themes highlight the evolving landscape of pharmacovigilance and the increasing complexity of drug safety evaluations.
  1. Real-World Evidence and Data Mining:
    There is a growing emphasis on utilizing real-world evidence and advanced data mining techniques to uncover adverse drug reactions and safety signals, reflecting a shift towards more data-driven approaches in pharmacovigilance.
  2. Machine Learning and Artificial Intelligence in Drug Safety:
    The integration of machine learning and AI technologies in pharmacovigilance is trending, with studies focusing on their potential to improve signal detection and risk assessment in drug safety.
  3. Patient-Centric Pharmacovigilance:
    An emerging focus on incorporating patient perspectives, experiences, and reported outcomes into drug safety evaluations is evident, aiming to enhance the relevance and applicability of findings.
  4. Safety of Novel Therapeutics and Biologics:
    Research is increasingly directed towards the safety profiles of novel therapeutics, including biologics and targeted therapies, particularly in oncology and immunology, reflecting the rapid advancement of these treatment modalities.
  5. Long-Term Safety and Post-Marketing Surveillance:
    There is a heightened interest in long-term safety studies and post-marketing surveillance, emphasizing the need to monitor drugs after they have been approved and widely prescribed.

Declining or Waning

As the field of drug safety evolves, certain themes within the journal have shown signs of declining prominence. This section highlights areas that are becoming less frequently addressed in recent publications.
  1. Traditional Pharmacovigilance Methods:
    There is a noticeable decline in studies focusing solely on traditional pharmacovigilance methods, as the field shifts towards more innovative and technology-driven approaches such as machine learning and big data analytics.
  2. Generalized Drug Safety Reviews:
    The trend towards more specialized and targeted safety evaluations has led to a decrease in broad, generalized reviews of drug safety, which may have been more common in earlier publications.
  3. Historical Drug Safety Studies:
    Research focusing on historical data or older medications is becoming less prevalent, as the journal increasingly prioritizes contemporary drugs and therapies.
  4. Single-Agent Safety Studies:
    There is a waning interest in studies examining the safety of single-agent therapies, with a growing focus on combination therapies and polypharmacy, especially in complex patient populations.
  5. Pharmacovigilance in Non-Pharmaceutical Contexts:
    The journal has seen a reduction in articles addressing pharmacovigilance in non-pharmaceutical contexts, such as dietary supplements or herbal products, which were previously more common.

Similar Journals

International Journal of Clinical Pharmacy

Fostering Global Collaboration in Clinical Pharmacy
Publisher: SPRINGERISSN: 2210-7703Frequency: 6 issues/year

The International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.

AMERICAN JOURNAL OF THERAPEUTICS

Championing Evidence-Based Approaches in Medicine
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1075-2765Frequency: 6 issues/year

The American Journal of Therapeutics is a prominent academic journal published by Lippincott Williams & Wilkins, specializing in the fields of medicine and pharmacology. With a rich history originating from 1960 and a commitment to advancing therapeutic knowledge through peer-reviewed research, this journal serves as a vital resource for professionals, researchers, and students alike. Its strong impact factor, alongside its classification in the Q2 and Q3 quartiles for diverse categories in medicine and pharmacology, underscores its significance in the academic community. The journal engages with the latest findings and innovations in therapeutic approaches, offering a platform for discussion and dissemination of research that addresses critical healthcare challenges. Although it operates under a traditional subscription model, the journal aims to foster open discourse within the therapeutic landscape, making it essential reading for those dedicated to enhancing patient care and pharmaceutical practices.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Bridging pharmacology and therapy for better patient outcomes.
Publisher: WILEY-HINDAWIISSN: 0269-4727Frequency: 1 issue/year

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

DRUGS & THERAPY PERSPECTIVES

Catalyzing Change in the World of Pharmacology and Therapy
Publisher: SPRINGERNATUREISSN: 1172-0360Frequency: 12 issues/year

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

CLINICAL DRUG INVESTIGATION

Transforming insights into impactful drug therapies.
Publisher: ADIS INT LTDISSN: 1173-2563Frequency: 12 issues/year

CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.

DRUGS IN R&D

Leading the charge in pharmacology and toxicology advancements.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

ANNALS OF PHARMACOTHERAPY

Empowering the Next Generation of Pharmacotherapy
Publisher: SAGE PUBLICATIONS INCISSN: 1060-0280Frequency: 12 issues/year

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

Safety

Advancing safety through innovative research.
Publisher: MDPIISSN: Frequency: 4 issues/year

Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Championing excellence in drug safety studies.
Publisher: WILEYISSN: 1053-8569Frequency: 12 issues/year

Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.

CLINICAL THERAPEUTICS

Exploring the intersection of research and clinical excellence.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.